The primary objective of this trial is to determine whether two doses of an extract from bran demonstrate a prebiotic effect on colonic bacteria (by modulating selected fecal microbial populations, particularly bifidobacteria). The secondary objective is to measure the potential beneficial effects of consuming an extract from bran on the following physiological parameters: laxation, fecal pH, fecal moisture and stool consistency, blood glucose and insulin concentrations, plasma lipid profiles and serum free fatty acids, colonic bacterial short chain fatty acid production, ammonia metabolism and protein degradation, and biomarkers of oxidative stress and inflammation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
65
Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
Provident CRC
Glen Ellyn, Illinois, United States
The primary outcome variable will be the difference between treatments in bifidobacteria counts per g of feces, expressed as log10 cells per g feces (dry weight)
Time frame: Baseline to end of each treatment (week 0 to week 3 of each treatment)
Other fecal bacterial counts
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
laxation
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
fecal pH
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
fecal moisture
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
stool consistency
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
blood glucose
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
Blood insulin
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
plasma lipid profiles
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
serum free fatty acids
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
fecal short chain fatty acids
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
fecal ammonia
Time frame: baseline to end of each treament (week 0 to week 3 of each treatment)
urinary para-cresol
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
urinary phenol (total)
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
urinary isoprostanes
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
oxidized low density lipoprotein (TBARS, conjugated dienes)
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
Urinary F2alpha-isoprostanes
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
Plasma antioxidant capacity (ORAC, FRAP)
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
serum amyloid A
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
hs-CRP
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
IL-6
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
TNF-alpha
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
gastrointestinal symptom survey
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
stool consistency (Bristol stool scale)
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
Quality of Life questionaire (Quality Metrics SF-36)
Time frame: baseline to end of each treatment (week 0 to week 3 of each treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.